Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Quest Diagnostics (DGX) and Fusion Pharmaceuticals (FUSN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK – Research Report), Quest Diagnostics (DGX – Research Report) and Fusion Pharmaceuticals (FUSN – Research Report).

Merck & Company (MRK)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Merck & Company yesterday and set a price target of $99.00. The company’s shares closed last Thursday at $107.34.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.7% and a 61.9% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Crispr Therapeutics AG, and Revance Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $119.95 average price target, a 12.6% upside from current levels. In a report issued on March 13, Wells Fargo also downgraded the stock to Hold with a $115.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Quest Diagnostics (DGX)

In a report released today, Erin Wright from Morgan Stanley maintained a Hold rating on Quest Diagnostics, with a price target of $158.00. The company’s shares closed last Thursday at $134.00.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 15.7% and a 65.4% success rate. Wright covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Phibro Animal Health, and Patterson Companies.

Quest Diagnostics has an analyst consensus of Hold, with a price target consensus of $156.44.

Fusion Pharmaceuticals (FUSN)

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Fusion Pharmaceuticals today and set a price target of $10.00. The company’s shares closed last Thursday at $4.13.

According to TipRanks.com, Ulz is a 2-star analyst with an average return of -0.3% and a 40.5% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Zentalis Pharmaceuticals, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fusion Pharmaceuticals with a $12.00 average price target, representing a 190.6% upside. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $19.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRK:

• Merck downgraded at Wells Fargo on valuation, lack of catalysts
• Merck downgraded to Equal Weight from Overweight at Wells Fargo
• Merck says Phase 2/3 CCTG IND.227/KEYNOTE-483 trial met primary endpoint
• Merck price target raised to $130 from $125 at Berenberg
• Merck price target raised to $123 from $116 at Guggenheim